ES2128031T3 - Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina. - Google Patents

Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina.

Info

Publication number
ES2128031T3
ES2128031T3 ES95900719T ES95900719T ES2128031T3 ES 2128031 T3 ES2128031 T3 ES 2128031T3 ES 95900719 T ES95900719 T ES 95900719T ES 95900719 T ES95900719 T ES 95900719T ES 2128031 T3 ES2128031 T3 ES 2128031T3
Authority
ES
Spain
Prior art keywords
polymorphic form
crystalline
mesilisilamino
propil
carboxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900719T
Other languages
English (en)
Inventor
Peter James Dunn
Michael Leslie Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2128031T3 publication Critical patent/ES2128031T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA FORMA AL POLIMORFICA, CRISTALINA DE UN COMPUESTO DE FORMULA (I) Y A LOS PROCEDIMIENTOS PARA SU PREPARACION, A LOS INTERMEDIOS USADOS EN SU PREPARACION Y A LAS COMPOSICIONES QUE LA CONTIENEN Y A LOS USOS DE LA FORMA {AL}POLIMORFICA.
ES95900719T 1993-12-04 1994-11-09 Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina. Expired - Lifetime ES2128031T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939324931A GB9324931D0 (en) 1993-12-04 1993-12-04 Glutaramide derivatives

Publications (1)

Publication Number Publication Date
ES2128031T3 true ES2128031T3 (es) 1999-05-01

Family

ID=10746163

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900719T Expired - Lifetime ES2128031T3 (es) 1993-12-04 1994-11-09 Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina.

Country Status (26)

Country Link
US (1) US6180665B1 (es)
EP (1) EP0731787B1 (es)
JP (1) JP2701988B2 (es)
KR (1) KR100203314B1 (es)
CN (1) CN1068586C (es)
AT (1) ATE175664T1 (es)
CA (1) CA2178085C (es)
CZ (1) CZ296428B6 (es)
DE (1) DE69416003T2 (es)
DK (1) DK0731787T3 (es)
EG (1) EG20562A (es)
ES (1) ES2128031T3 (es)
FI (1) FI120305B (es)
GB (1) GB9324931D0 (es)
GR (1) GR3029590T3 (es)
HU (1) HU225959B1 (es)
IL (1) IL111791A (es)
MY (1) MY115430A (es)
NO (1) NO306714B1 (es)
NZ (1) NZ276087A (es)
PE (1) PE9296A1 (es)
PL (1) PL178559B1 (es)
RU (1) RU2131869C1 (es)
TW (2) TW434210B (es)
WO (1) WO1995015308A1 (es)
ZA (1) ZA949595B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7004344B2 (en) 2000-08-29 2006-02-28 Tolko Industries Ltd. Collapsible bin
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
US6975515B2 (en) 2001-08-15 2005-12-13 Agilent Technologies, Inc. Electrical module
CA2513837A1 (en) * 2003-02-12 2004-08-26 Paul Adriaan Van Der Schaaf Crystalline forms of pitavastatin calcium
WO2005123702A1 (en) * 2004-06-15 2005-12-29 Pfizer Limited Neutral endopeptidase inhibitor polymorph
CN109350736A (zh) * 2018-09-20 2019-02-19 南通大学 防治运动病、梅尼埃病的药物及心房钠尿肽的医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820844D0 (en) 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use

Also Published As

Publication number Publication date
IL111791A0 (en) 1995-01-24
CA2178085C (en) 2002-09-03
CN1142816A (zh) 1997-02-12
EP0731787B1 (en) 1999-01-13
HU9601506D0 (en) 1996-07-29
PL314794A1 (en) 1996-09-30
KR960706470A (ko) 1996-12-09
AU684114B2 (en) 1997-12-04
RU2131869C1 (ru) 1999-06-20
EG20562A (en) 1999-08-30
KR100203314B1 (ko) 1999-06-15
NO962294D0 (no) 1996-06-04
DE69416003D1 (en) 1999-02-25
CA2178085A1 (en) 1995-06-08
FI962322A0 (fi) 1996-06-03
PE9296A1 (es) 1996-04-04
GB9324931D0 (en) 1994-01-26
JPH09500654A (ja) 1997-01-21
NO306714B1 (no) 1999-12-13
AU8142494A (en) 1995-06-19
WO1995015308A1 (en) 1995-06-08
TW534901B (en) 2003-06-01
HUT74683A (en) 1997-01-28
DE69416003T2 (de) 1999-05-27
DK0731787T3 (da) 1999-08-30
FI120305B (fi) 2009-09-15
MY115430A (en) 2003-06-30
CZ296428B6 (cs) 2006-03-15
PL178559B1 (pl) 2000-05-31
CN1068586C (zh) 2001-07-18
NZ276087A (en) 1997-11-24
GR3029590T3 (en) 1999-06-30
NO962294L (no) 1996-06-04
IL111791A (en) 2002-09-12
EP0731787A1 (en) 1996-09-18
FI962322A (fi) 1996-06-03
HU225959B1 (en) 2008-01-28
TW434210B (en) 2001-05-16
ZA949595B (en) 1996-06-03
JP2701988B2 (ja) 1998-01-21
CZ160496A3 (en) 1996-11-13
US6180665B1 (en) 2001-01-30
ATE175664T1 (de) 1999-01-15

Similar Documents

Publication Publication Date Title
BG103485A (en) Ketobanzamides as calpain inhibitors
DE69831868D1 (en) Antithrombosemittel
NO971538L (no) Purin- og guaninforbindelser som inhibitorer for PNP
IL126610A0 (en) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors
ATE297203T1 (de) Antithrombotische mitteln
BG103415A (en) Heteroaryl succinamides and their application as inhibitors of metalloproteinase
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
NZ279397A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
YU41199A (sh) Hinoksalindioni
CA2107223A1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
CA2124083A1 (en) Preparation of substituted piperidines
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
ES2128031T3 (es) Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina.
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
MY129094A (en) Condensed polycyclic compounds
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
ATE282608T1 (de) Chinoxalindionen
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 731787

Country of ref document: ES